These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27755105)

  • 41. Evaluation of the Innate Immune Modulator Acitretin as a Strategy To Clear the HIV Reservoir.
    Garcia-Vidal E; Castellví M; Pujantell M; Badia R; Jou A; Gomez L; Puig T; Clotet B; Ballana E; Riveira-Muñoz E; Esté JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Which therapeutic strategy will achieve a cure for HIV-1?
    Cillo AR; Mellors JW
    Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Secreted factors induced by PKC modulators do not indirectly cause HIV latency reversal.
    Moran JA; Ranjan A; Hourani R; Kim JT; Wender PA; Zack JA; Marsden MD
    Virology; 2023 Apr; 581():8-14. PubMed ID: 36842270
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/β-catenin/TCF1 axis in CD4
    Wen J; Li X; Zhao QX; Yang XF; Wu ML; Yan Q; Chang J; Wang H; Jin X; Su X; Deng K; Chen L; Wang JH
    Emerg Microbes Infect; 2022 Dec; 11(1):391-405. PubMed ID: 34985411
    [No Abstract]   [Full Text] [Related]  

  • 45. Therapeutics for HIV-1 reactivation from latency.
    Sgarbanti M; Battistini A
    Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?
    Rasmussen TA; Lewin SR
    Curr Opin HIV AIDS; 2016 Jul; 11(4):394-401. PubMed ID: 26974532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo.
    Ren Y; Huang SH; Patel S; Alberto WDC; Magat D; Ahimovic D; Macedo AB; Durga R; Chan D; Zale E; Mota TM; Truong R; Rohwetter T; McCann CD; Kovacs CM; Benko E; Wimpelberg A; Cannon C; Hardy WD; Bosque A; Bollard CM; Jones RB
    J Clin Invest; 2020 May; 130(5):2542-2559. PubMed ID: 32027622
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epigenetic Compound Screening Uncovers Small Molecules for Reactivation of Latent HIV-1.
    Zutz A; Chen L; Sippl F; Humpe A; Schölz C
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of monotherapy on HIV-1 reservoir, immune activation, and co-infection with Epstein-Barr virus.
    Petrara MR; Cattelan AM; Sasset L; Freguja R; Carmona F; Sanavia S; Zanchetta M; Del Bianco P; De Rossi A
    PLoS One; 2017; 12(9):e0185128. PubMed ID: 28926641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
    Badia R; Grau J; Riveira-Muñoz E; Ballana E; Giannini G; Esté JA
    Antiviral Res; 2015 Nov; 123():62-9. PubMed ID: 26348004
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of proximal biomarkers of PKC agonism and evaluation of their role in HIV reactivation.
    Vemula SV; Maxwell JW; Nefedov A; Wan BL; Steve J; Newhard W; Sanchez RI; Tellers D; Barnard RJ; Blair W; Hazuda D; Webber AL; Howell BJ
    Antiviral Res; 2017 Mar; 139():161-170. PubMed ID: 27889530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs.
    Ait-Ammar A; Kula A; Darcis G; Verdikt R; De Wit S; Gautier V; Mallon PWG; Marcello A; Rohr O; Van Lint C
    Front Microbiol; 2019; 10():3060. PubMed ID: 32038533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
    Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
    J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.
    Walker-Sperling VE; Cohen VJ; Tarwater PM; Blankson JN
    J Virol; 2015 Sep; 89(18):9631-8. PubMed ID: 26178987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effective in vivo reactivation of HIV-1 latency reservoir via oral administration of EK-16A-SNEDDS.
    Yang J; Shi C; Cheng Y; Zhu Y; Yang X; Liang Y; Liang H; Lin Q; Li M; Xun J; Liu J; Yin C; Qi J; Zhu H
    Eur J Pharm Biopharm; 2024 Aug; 201():114353. PubMed ID: 38885911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
    Offersen R; Nissen SK; Rasmussen TA; Østergaard L; Denton PW; Søgaard OS; Tolstrup M
    J Virol; 2016 May; 90(9):4441-4453. PubMed ID: 26889036
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen.
    Liu H; Hu PW; Dubrulle J; Stossi F; Nikolai BC; Mancini MA; Rice AP
    PLoS One; 2021; 16(4):e0244771. PubMed ID: 33914760
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing.
    Khoury G; Purcell DFJ
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30735158
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nicotinamide activates latent HIV-1 ex vivo in ART suppressed individuals, revealing higher potency than the association of two methyltransferase inhibitors, chaetocin and BIX01294.
    Samer S; Arif MS; Giron LB; Zukurov JPL; Hunter J; Santillo BT; Namiyama G; Galinskas J; Komninakis SV; Oshiro TM; Sucupira MC; Janini LM; Diaz RS
    Braz J Infect Dis; 2020; 24(2):150-159. PubMed ID: 32105620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.